The race for access: How the FAIR Act could reclaim U.S. biotech leadership

Clinical trial access in the United States faces a growing competitiveness crisis as other nations, including China, accelerate their biomedical innovation pipelines. The FAIR Act addresses this by establishing a harmonized, accelerated 30-day review pathway for clinical trials and therapies already approved by trusted regulatory authorities like the EMA and Health Canada. For patients with rare, life-threatening conditions such as pulmonary fibrosis, this legislation offers a critical lifeline, preventing the need to travel abroad for potentially life-saving treatments. Max Bronstein, CEO of Aviva Strategies, and Teresa Barnes, leader of PF Warriors, emphasize that current regulatory delays force patients to endure unnecessary waiting periods, often with fatal consequences. By streamlining these processes, the bill aims to restore U.S. leadership in medical research while ensuring domestic patients gain timely access to global advancements in care.